OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	150
Strategies for targeting RNA with small molecule drugs	109
Advances in ion channel high throughput screening: where are we in 2023?	77
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	68
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	66
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	60
Advances in the discovery of drugs that treat pulmonary arterial hypertension	43
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	39
Tools and techniques for the discovery of therapeutic aptamers: recent advances	38
γ-Secretase: once and future drug target for Alzheimer’s disease	38
What is the plausibility that all drugs will be designed by computers by the end of the decade?	38
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	33
Methods in marine natural product drug discovery: what’s new?	33
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	33
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	31
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder	30
The rules often neglected in current medicinal chemistry	30
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	30
A cautionary tale of paradox and false positives in cannabidiol research	30
An update on knowledge graphs and their current and potential applications in drug discovery	29
Guided structure-based ligand identification and design via artificial intelligence modeling	29
Virtual screening: hope, hype, and the fine line in between	27
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	26
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	26
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	26

Water in drug design: pitfalls and good practices